20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Bioventus Inc (BVS) operates in the MEDICAL DEVICES industry and is headquartered in Durham, United States with about 950 employees. Its market capitalization is roughly $882 million. In the fiscal year ended 2025-12-31, BVS reported $568M in revenue and $23M in net income.
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally.
Interactive charts & full statements → Open the BVS valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $582M | $568M | $573M | $512M | $512M | $431M | $321M | $340M | $319M | $292M | $274M | $254M | $243M | $232M |
| Gross Profit | $396M | $382M | $388M | $328M | $331M | $303M | $234M | $249M | $235M | $200M | $183M | $179M | $168M | $161M |
| Gross Margin % | 68.0% | 67.3% | 67.7% | 64.1% | 64.6% | 70.2% | 72.7% | 73.3% | 73.6% | 68.5% | 66.7% | 70.7% | 69.3% | 69.3% |
| Operating Income (EBIT) | $62M | $59M | ($12M) | ($82M) | ($167M) | $12M | $21M | $31M | $26M | $27M | $15M | ($17M) | $0M | ($8M) |
| Operating Margin % | 10.6% | 10.3% | -2.1% | -16.0% | -32.7% | 2.8% | 6.6% | 9.2% | 8.0% | 9.2% | 5.4% | -6.5% | 0.0% | -3.5% |
| Net Income | $54M | $23M | ($34M) | ($156M) | ($159M) | $19M | $16M | $7M | ($12M) | ($2M) | ($18M) | ($34M) | ($13M) | ($22M) |
| Net Margin % | 9.4% | 4.0% | -5.9% | -30.5% | -31.0% | 4.5% | 5.1% | 2.0% | -3.8% | -0.6% | -6.5% | -13.5% | -5.3% | -9.6% |
| EBITDA | $93M | $99M | $39M | ($23M) | ($122M) | $45M | $54M | $62M | $55M | $60M | $44M | $39M | $29M | $16M |
| Earnings Per Share (EPS) | $0.78 | $0.33 | $-0.51 | $-2.49 | $-2.59 | $0.43 | $0.44 | $0.12 | $-0.21 | $-0.03 | $-0.32 | $-0.61 | $-0.23 | $-0.40 |
| Shares Outstanding (M) | 71M | 69M | 65M | 63M | 61M | 45M | 38M | 57M | 57M | 57M | 57M | 56M | 56M | 56M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $153M | $132M | $158M | $139M | $148M | $124M | $154M | $139M |
| Gross Profit | $106M | $90M | $107M | $93M | $101M | $81M | $103M | $94M |
| Gross Margin % | 69.0% | 67.9% | 68.1% | 67.0% | 68.2% | 65.8% | 66.8% | 67.3% |
| Operating Income (EBIT) | $19M | $9M | $22M | $12M | $19M | $5M | $8M | $4M |
| Operating Margin % | 12.5% | 6.7% | 13.8% | 8.7% | 12.6% | 4.0% | 5.2% | 2.9% |
| Net Income | $33M | $3M | $15M | $3M | $7M | ($3M) | $0M | ($5M) |
| Net Margin % | 21.8% | 2.4% | 9.3% | 2.3% | 5.1% | -2.1% | -0.1% | -3.5% |
| EBITDA | $19M | $20M | $31M | $22M | $30M | $16M | $22M | $17M |
| Earnings Per Share (EPS) | $0.47 | $0.04 | $0.21 | $0.05 | $0.11 | $-0.04 | $-0.00 | $-0.07 |
| Shares Outstanding (M) | 71M | 70M | 69M | 69M | 69M | 66M | 65M | 65M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | $97M | $74M | $39M | $15M | ($14M) | $23M | $72M | $41M | $45M | $19M | $15M | $3M |
| Capital Expenditures (CapEx) | $3M | $3M | $1M | $7M | $1M | $7M | $21M | $8M | $6M | $7M | $21M | $6M |
| Free Cash Flow (FCF) | $94M | $71M | $38M | $8M | ($15M) | $16M | $51M | $32M | $39M | $11M | ($6M) | ($4M) |
| FCF Margin % | 16.2% | 12.6% | 6.6% | 1.6% | -2.9% | 3.6% | 15.9% | 9.5% | 12.3% | 4.5% | -2.4% | -1.6% |
| Dividends Paid | — | — | — | — | $9M | $0M | $20M | $9M | $8M | $1M | $2M | $3M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | $20M | $9M | $38M | $30M | $26M | ($19M) | $19M | $10M |
| Capital Expenditures (CapEx) | $1M | $1M | $1M | $0M | $1M | $1M | $1M | $0M |
| Free Cash Flow (FCF) | $19M | $8M | $37M | $30M | $25M | ($20M) | $19M | $10M |
| FCF Margin % | 12.3% | 6.3% | 23.7% | 21.4% | 17.1% | -16.3% | 12.2% | 7.4% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2015-12-31 | 2014-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $673M | $684M | $728M | $811M | $1.4B | $1.2B | $494M | $472M | $443M | $487M | $430M |
| Cash & Cash Equivalents | $29M | $51M | $42M | $37M | $30M | $44M | $87M | $65M | $43M | $5M | $16M |
| Total Liabilities | $396M | $455M | $542M | $590M | $960M | $692M | $350M | $327M | $297M | $295M | $253M |
| Total Debt (Short + Long-Term) | $253M | $298M | $336M | $395M | $418M | $358M | $188M | $198M | $195M | $38M | $8M |
| Total Shareholders' Equity | $228M | $184M | $148M | $174M | $325M | $459M | $142M | $143M | $145M | $192M | $177M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive BVS viewer.
About TickerBase · Data methodology & sources · Privacy · Terms